Infection Rate and Risk Factors in Patients Treated With Azacitidine

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):e141-2. doi: 10.1016/j.clml.2015.07.001. Epub 2015 Jul 17.

Authors

M Orero¹, C Villegas², S Ortiz², K P Javier², S Costa², P L Pérez², M Roig², M Linares²

Affiliations

¹ Department of Hematology, Consorcio Hospital General Universitario, Valencia, Spain. Electronic address: orero_may@gva.es.
² Department of Hematology, Consorcio Hospital General Universitario, Valencia, Spain.

PMID: 26257105
DOI: 10.1016/j.clml.2015.07.001

No abstract available

Publication types

Letter
Comment

MeSH terms

Antimetabolites, Antineoplastic / administration & dosage*
Azacitidine / administration & dosage*
Bacterial Infections / etiology*
Female
Humans
Leukemia, Myeloid, Acute / drug therapy*
Male
Myelodysplastic Syndromes / drug therapy*
Virus Diseases / etiology*

Substances

Antimetabolites, Antineoplastic
Azacitidine